GPR56 Outperforms CD319 as a Discriminative Marker for CD4 + Cytotoxic T Lymphocytes and Is Elevated in Primary Sjögren's Syndrome
Immunology · 2026
DOI: 10.1111/imm.70073 ↗At a glance
Journal article in Immunology, 2026. Written by Ziqi Xiong and 10 co-authors. Institution: Department of Clinical Laboratory, Peking University People's Hospital, Beijing, China. Major MEDLINE topics: Sjogren's Syndrome, Receptors, G-Protein-Coupled, T-Lymphocytes, Cytotoxic, CD4-Positive T-Lymphocytes. Cited 5 times so far (Crossref); 52 references. Funded by: National Natural Science Foundation of China, Peking University People's Hospital Scientific Research Development Funds, Open Research Fund of the National Centre for Protein Sciences at Peking University in Beijing.
Abstract (original language)
Cytotoxic T lymphocytes (CTLs), especially CD4 + CTLs, play a critical role in immune responses against infections and cancers. Nevertheless, the surface markers that define CD4 + CTLs remain incompletely characterised, which limits their diagnostic and therapeutic potential. In this study, we investigate CD319 (SLAMF7) and GPR56 as potential surface markers of CD4 + CTLs, with a focus on their cytotoxic functions and relevance in primary Sjögren's syndrome (pSS). Using single‐cell RNA sequencing and flow cytometry, we detected strong co‐expression of GPR56 with cytotoxic effector molecules such as granzyme B in CD4 + T cells. Notably, pSS patients showed an elevated frequency of CD4 + GPR56 + T cells, which was associated with disease severity, indicating their potential contribution to pSS pathogenesis. Comparative transcriptomic analysis revealed distinct gene expression profiles between CD4 + GPR56 + and CD4 + GPR56 − T cells, with enriched pathways related to immune activation and cytotoxicity. Together, our results identify GPR56 as a novel and functionally significant surface marker for CD4 + CTLs, providing new insights into their role in autoimmune disorders and their potential for targeted therapeutic strategies.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Clinical Laboratory, Peking University People's Hospital, Beijing, China.
- School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
- Department of Immunology, NHC Key Laboratory of Medical Immunology (Peking University), Medicine Innovation Center for Fundamental Research on Major Immunology-Related Diseases, School of Basic Medical Sciences, Peking…
- Peking University Center for Human Disease Genomics, Peking University Health Science Center, Beijing, China.
ORCID profiles: Pingzhang Wang, Chen Liu
Funding
- National Natural Science Foundation of China
- Peking University People's Hospital Scientific Research Development Funds
- Open Research Fund of the National Centre for Protein Sciences at Peking University in Beijing
- Peking University People's Hospital
Cite
APA
Xiong, Z., Gao, Y., He, J., Bahabayi, A., Zeng, X., Zhang, Z., Hasimu, A., Zhang, Y., Guo, S., Wang, P., & Liu, C. (2026). GPR56 Outperforms CD319 as a Discriminative Marker for CD4 + Cytotoxic T Lymphocytes and Is Elevated in Primary Sjögren's Syndrome. Immunology. https://doi.org/10.1111/imm.70073
Vancouver
Xiong Z, Gao Y, He J, Bahabayi A, Zeng X, Zhang Z, et al. GPR56 Outperforms CD319 as a Discriminative Marker for CD4 + Cytotoxic T Lymphocytes and Is Elevated in Primary Sjögren's Syndrome. Immunology. 2026. doi:10.1111/imm.70073
BibTeX
@article{Xiong2026,
author = {Xiong, Ziqi and Gao, Yiming and He, Junru and Bahabayi, Ayibaota and Zeng, Xingyue and Zhang, Zhonghui and Hasimu, Ainizati and Zhang, Yangyang and Guo, Siyu and Wang, Pingzhang and Liu, Chen},
title = {GPR56 Outperforms CD319 as a Discriminative Marker for CD4 + Cytotoxic T Lymphocytes and Is Elevated in Primary Sjögren's Syndrome},
journal = {Immunology},
year = {2026},
doi = {10.1111/imm.70073}
}
EUVIMED